서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

Login

S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 11 of 11

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2016-03	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial Harbeck, Nadia; Huang, Chiun-Sheng; Hurvitz, Sara; Yeh, Dah-Cherng; Shao, Zhimin; Im, Seock-Ah; Jung, Kyung Hae; Shen, Kunwei; Ro, Jungsil; Jassem, Jacek; Zhang, Qingyuan; Im, Young-Hyuck; Wojtukiewicz, Marek; Sun, Qiang; Chen, Shin-Cheh; Goeldner, Rainer-Georg; Uttenreuther-Fischer, Martina; Xu, Binghe; Piccart-Gebhart, Martine The Lancet Oncology, Vol.17 No.3, pp.357-366	DOI
2017-09	A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer Reynolds, Kerry Lynn; Bedard, Philippe L.; Lee, Se-Hoon; Lin, Chia-Chi; Tabernero, Josep; Alsina, Maria; Cohen, Ezra; Baselga, Jose; Blumenschein, George, Jr.; Graham, Donna M.; Garrido-Laguna, Ignacio; Juric, Dejan; Sharma, Sunil; Salgia, Ravi; Seroutou, Abdelkader; Tian, Xianbin; Fernandez, Rose; Morozov, Alex; Sheng, Qing; Ramkumar, Thiruvamoor; Zubel, Angela; Bang, Yung-Jue BMC Cancer, Vol.17, p. 646	view file DOI
2018-03	Phase III, Randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE Johnston, Stephen R. D.; Hegg, Roberto; Im, Seock-Ah; Park, In Hae; Burdaeva, Olga; Kurteva, Galina; Press, Michael F.; Tjulandin, Sergei; Iwata, Hiroji; Simon, Sergio D.; Kenny, Sarah; Sarp, Severine; Izquierdo, Miguel A.; Williams, Lisa S.; Gradishar, William J. Journal of Clinical Oncology, Vol.36 No.8, pp.741-748	DOI
2018-04	Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer Pivot, Xavier; Bondarenko, Igor; Nowecki, Zbigniew; Dvorkin, Mikhail; Trishkina, Ekaterina; Ahn, Jin-Hee; Vinnyk, Yuriy; Im, Seock-Ah; Sarosiek, Tomasz; Chatterjee, Sanjoy; Wojtukiewicz, Marek Z.; Moiseyenko, Vladimir; Shparyk, Yaroslav; Bello, Maximino, III; Semiglazov, Vladimir; Song, Sujeong; Lim, Jaeyun Journal of Clinical Oncology, Vol.36 No.10, pp.968-974	DOI
2019-11	A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer Kim, Tae-Yong; Han, Hye Sook; Lee, Keun-Wook; Zang, Dae Young; Rha, Sun Young; Park, Young lee; Kim, Jin-Soo; Lee, Kyung-Hun; Park, Se Hoon; Song, Eun-Kee; Jung, Soo-A; Lee, NaMi; Kim, Yeul Hong; Cho, Jae Yong; Bang, Yung-Jue Gastric Cancer, Vol.22 No.6, pp.1206-1214	DOI
2020-06	Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer Shitara, Kohei; Bang, Yung-Jue; Iwasa, Satoru; Sugimoto, Naotoshi; Ryu, Min-Hee; Sakai, Daisuke; Chung, Hyun-Cheol; Kawakami, Hisato; Yabusaki, Hiroshi; Lee, Jeeyun; Saito, Kaku; Kawaguchi, Yoshinori; Kamio, Takahiro; Kojima, Akihito; Sugihara, Masahiro; Yamaguchi, Kensei New England Journal of Medicine, Vol.382 No.25, pp.2419-2430	DOI
2021-01	Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE Johnston, Stephen R. D.; Hegg, Roberto; Im, Seock-Ah; Park, In Hae; Burdaeva, Olga; Kurteva, Galina; Press, Michael F.; Tjulandin, Sergei; Iwata, Hiroji; Simon, Sergio D.; Kenny, Sarah; Sarp, Severine; Izquierdo, Miguel A.; Williams, Lisa S.; Gradishar, William J. Journal of Clinical Oncology, Vol.39 No.1, pp.79-89	DOI
2022-03	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer Cortes, J.; Kim, S.-B.; Chung, W.-P.; Im, S.-A.; Park, Y.H.; Hegg, R.; Kim, M.H.; Tseng, L.-M.; Petry, V.; Chung, C.-F.; Iwata, H.; Hamilton, E.; Curigliano, G.; Xu, B.; Huang, C.-S.; Kim, J.H.; Chiu, J.W.Y.; Pedrini, J.L.; Lee, C.; Liu, Y.; Cathcart, J.; Bako, E.; Verma, S.; Hurvitz, S.A. New England Journal of Medicine, Vol.386 No.12, pp.1142-1154	DOI
2023-01	Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial Hurvitz, Sara A.; Hegg, Roberto; Chung, Wei-Pang; Im, Seock-Ah; Jacot, William; Ganju, Vinod; Chiu, Joanne Wing Yan; Xu, Binghe; Hamilton, Erika; Madhusudan, Srinivasan; Iwata, Hiroji; Altintas, Sevilay; Henning, Jan-Willem; Curigliano, Giuseppe; Perez-Garcia, Jose Manuel; Kim, Sung-Bae; Petry, Vanessa; Huang, Chiun-Sheng; Li, Wei; Frenel, Jean-Sebastien; Antolin, Silvia; Yeo, Winnie; Bianchini, Giampaolo; Loi, Sherene; Tsurutani, Junji; Egorov, Anton; Liu, Yali; Cathcart, Jillian; Ashfaque, Shahid; Cortes, Javier The Lancet, Vol.401 No.10371, pp.105-117	DOI
2023-05	Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial André, Fabrice; Hee Park, Yeon; Kim, Sung-Bae; Takano, Toshimi; Im, Seock-Ah; Borges, Giuliano; Lima, Joao Paulo; Aksoy, Sercan; Gavila Gregori, Joaquin; De Laurentiis, Michelino; Bianchini, Giampaolo; Roylance, Rebecca; Miyoshi, Yasuo; Armstrong, Anne; Sinha, Rajni; Ruiz Borrego, Manuel; Lim, Elgene; Ettl, Johannes; Yerushalmi, Rinat; Zagouri, Flora; Duhoux, Francois P; Fehm, Tanja; Gambhire, Dhiraj; Cathcart, Jillian; Wu, Cai; Chu, Changan; Egorov, Anton; Krop, Ian The Lancet, Vol.401 No.10390, pp.1773-1785	DOI
2024	A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15) Baek, Sun Kyung; Jeong, Jae-ho; Jung, Kyunghae; Ahn, Hee Kyung; Kim, Min Hwan; Sohn, Joohyuk; Park, In Hae; Ahn, Jin Seok; Lee, Dae-Won; Im, Seock-Ah; Sim, Sung Hoon; Lee, Keun Seok; Hyun Kim, Jee; Shim, Hyun-Jeong; Chae, Yeesoo; Koh, Su-Jin; Lee, Hyorak; Lee, Jieun; Byun, Jae-Ho; Seol, Youngmi; Lee, Eun Mi; Jee, Hee-Jung; An, Hyonggin; Park, Eun Byeol; Suh, Young Ju; Lee, Kyoung Eun; Park, Yeon Hee Therapeutic Advances in Medical Oncology, Vol.16, pp.1-15	DOI

1